Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Increasing Flu Vaccination Through Evidence-Based Nudges (INFLUENCE)

10 de noviembre de 2026 actualizado por: Elena Azzolini, Istituto Clinico Humanitas

Nudge-based Strategies to Increase Influenza Vaccination Uptake Among Health and Social Care Personnel: a Multicentre Cluster-randomised Trial

This study aims to find out whether changing the wording and content of workplace emails can encourage more healthcare and non-healthcare staff to get a seasonal flu vaccine. The main question is whether emails that highlight the benefits of vaccination, the possible consequences of not getting vaccinated, or vaccination rates among colleagues are more effective than standard information emails.

The study will take place during the 2026-2027 flu vaccination campaign across 17 healthcare and social care organizations in Lombardy, Italy. Approximately 45,000 eligible workers are expected to be included, covering both staff who provide patient care and those in administrative, technical, and support roles.

Workplace groups, such as departments or organizational units, are randomly assigned to one of four email communication approaches:

  • Standard information (control): emails communicating that the vaccination campaign is ongoing and that it is possible to get vaccinated.
  • Benefits of vaccination (gain framing): emails emphasizing the potential benefits of vaccination for workers, patients, colleagues, and the organization.
  • Consequences of not getting vaccinated (loss framing): emails emphasizing the possible risks and negative consequences for workers, patients, colleagues, and the organization.
  • Vaccination among colleagues (social norms): emails and follow-up updates showing vaccination progress and, where possible, comparing vaccination rates in the recipient's workplace group with those in other groups.

Researchers will use existing vaccination and employment records to compare the percentage of workers who receive a flu vaccine in each group by the end of the campaign. They will also examine whether the emails encourage earlier vaccination and whether their effects differ across workplaces and staff groups. Where suitable records are available, they will explore differences in sickness absence during the campaign.

Vaccination will remain voluntary, and all workers will continue to have access to the usual vaccination services. The study involves workplace emails and the use of existing records; no additional medical visits, tests, or procedures are required.

The findings will help healthcare organizations decide whether simple changes to routine communication can improve staff flu vaccination rates and which approach works best.

Descripción general del estudio

Descripción detallada

Seasonal influenza represents a major public health issue, associated with morbidity, mortality, pressure on healthcare services, workforce absenteeism and risk of transmission in care settings. Influenza vaccination of healthcare and non-healthcare workers employed in healthcare and social care organisations is an important preventive measure, not only for individual protection, but also for the indirect protection of frail patients, reduction of transmission in healthcare settings, preservation of continuity of care and resilience of healthcare services. Despite the availability of influenza vaccination and public health recommendations, vaccination uptake among healthcare and non-healthcare workers remains suboptimal and variable across organisations, professional profiles and organisational units. Communication strategies informed by behavioural science, commonly referred to as "nudges", represent low-cost, scalable organisational interventions that may guide individuals towards preventive behaviours while preserving individual autonomy. The study aims to evaluate the effectiveness of an organisational and behavioural communication strategy with potential impact on prevention, quality of care pathways, workforce resilience and public health.

Primary objective: to evaluate the effectiveness of nudge-based communication strategies, assigned at organisational cluster level, in increasing influenza vaccination uptake among eligible healthcare and non-healthcare workers during the 2026-2027 influenza vaccination campaign compared with standard institutional communication.

Secondary objectives:

  • to compare the relative effectiveness of the different communication arms, including standard communication, gain framing, loss framing and social norms/peer feedback;
  • to assess the change in influenza vaccination uptake during the 2026-2027 campaign compared with the 2025-2026 campaign, where historical data are available; to evaluate time to vaccination;
  • to explore heterogeneity of effect by organisational cluster, healthcare/non-healthcare area and previous vaccination history, where available;
  • to assess sickness absence indicators at cluster level during the vaccination campaign, where such data are available and comparable across participating organisations;
  • to generate evidence to inform future organisational, regional and potentially national vaccination communication and prevention policies.

Primary endpoint:

Influenza vaccination uptake during the 2026-2027 influenza vaccination campaign, defined as the proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination by the end of the observation period. Documented vaccinations will be considered irrespective of the setting in which they are administered, including vaccinations administered within the participating organisation or through other authorised vaccination pathways, where captured by ARVAX or other applicable regional administrative data sources.

Secondary endpoints:

  • Absolute percentage-point change in influenza vaccination uptake between the 2026-2027 campaign and the 2025-2026 campaign, at cluster level;
  • Time to vaccination, defined as the number of days between delivery of the communication assigned to the cluster and the documented date of influenza vaccination;
  • Sickness absence indicators at cluster level during the vaccination campaign, including number of sickness absence days and/or sickness absence rates standardised by eligible population or person-time, according to data availability and quality.

Population and patient selection criteria: The study population consists of healthcare and non-healthcare workers eligible for influenza vaccination during the 2026-2027 campaign and belonging to organisational clusters included in the study within the 17 participating Lombardy organisations.

In this protocol, the term "patients/subjects" should be understood as "study participants/workers", since the study is not conducted on assisted patients. Inclusion criteria: employment or affiliation with one of the 17 participating organisations; belonging to an included and randomised organisational cluster; eligibility for influenza vaccination according to applicable regional/organisational recommendations; availability in administrative data flows required to define the denominator; and availability of vaccination outcome data through administrative, regional or organisational data sources.

Exclusion criteria: non-eligibility for influenza vaccination; lack of minimum data required for denominator definition, cluster attribution or outcome ascertainment; belonging to clusters that are not classifiable, mappable or randomizable; termination of employment/affiliation before the start of the campaign if not exposed to the possibility of organisational vaccination; or any other administrative condition preventing correct attribution to cluster, study arm or outcome.

Study design: This is a pragmatic, multicentre, four-arm, parallel-group, cluster-randomised, non-pharmacological procedural-organisational interventional study, prospectively implemented during the 2026-2027 influenza vaccination campaign. Randomisation will occur at the level of organisational clusters, defined as organisational units uniformly identified across participating centres according to FLUPER or another consistent organisational classification available within the participating organisations. Clusters will be allocated in a 1:1:1:1 ratio to one of four arms: standard communication, gain framing, loss framing, and social norms/peer feedback. Outcomes and denominators will be assessed using routinely available administrative, regional and organisational data flows, including FLUPER, the regional healthcare workforce administrative flow used to support workforce denominator definition and organisational classification, and ARVAX, the regional vaccination registry/database used to ascertain vaccination uptake; where available, organisational workforce or human resources data flows used to assess cluster-level sickness absence indicators will be used.

Description of the intervention: The intervention consists of institutional e-mail communications sent by the Vaccination Unit or the competent organisational function of each participating organisation, with content differentiated according to the study arm assigned to the cluster.

  • Arm 1 - Standard communication: standard e-mail containing information on the launch of the influenza vaccination campaign, access procedures, vaccination sites, opening hours and booking channels.
  • Arm 2 - Gain framing: e-mail emphasising the benefits of vaccination for the worker, patients, colleagues and the organisation.
  • Arm 3 - Loss framing: e-mail emphasising the risks and potential negative consequences of non-vaccination for the worker, patients, colleagues and the organisation.
  • Arm 4 - Social norms / peer feedback: periodic e-mails providing updates on campaign progress and, where feasible, comparison between the vaccination uptake rate of the recipient's cluster and that of other clusters or the overall cluster average.

The comparator is standard/informational communication, corresponding to routine communication on the launch of the vaccination campaign and on access procedures.

Number of participants planned: The overall expected number of participants will be determined based on FLUPER/organisational data flows and other available administrative sources from the 17 participating organisations before final randomisation. All eligible healthcare and non-healthcare workers belonging to the randomised clusters are expected to be included.

Total number planned: approximately 45,000 healthcare and non-healthcare workers across all 17 participating organisations, subject to confirmation based on the final eligible workforce denominator derived from FLUPER and/or organisational administrative data flows before randomisation. Number planned per arm: approximately one quarter of the overall eligible population, depending on the number and size of randomised cluster

Tipo de estudio

Intervencionista

Inscripción (Estimado)

45000

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Bergamo, Italia
        • ATS Bergamo
      • Brescia, Italia
        • ASST Spedali Civili di Brescia
      • Crema, Italia
        • ASST Crema
      • Desenzano del Garda, Italia
        • ASST Garda
      • Garbagnate Milanese, Italia
        • ASST Rhodense
      • Legnano, Italia
        • ASST Ovest Milanese
      • Lodi, Italia
        • ASST Lodi
      • Milan, Italia
        • Istituto Europeo di Oncologia
      • Milan, Italia
        • ASST Fatebenefratelli-Sacco
      • Milan, Italia
        • ASST Santi Paolo e Carlo
      • Paderno Dugnano, Italia
        • Clinica Polispecialistica San Carlo
      • Pavia, Italia
        • ASST Pavia
      • Pavia, Italia
        • ATS Pavia
      • Sondrio, Italia
        • ASST Valtellina e Alto Lario
      • Treviglio, Italia
        • ASST Bergamo Ovest
      • Vimercate, Italia
        • ASST Brianza
    • Lombardy
      • Milan, Lombardy, Italia, 20089
        • Istituto Clinico Humanitas

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion criteria:

  • employment or affiliation with one of the 17 participating organisations;
  • belonging to an included and randomised organisational cluster;
  • availability in administrative data flows required to define the denominator;
  • availability of vaccination outcome data through administrative regional data sources.

Exclusion criteria:

  • lack of minimum data required for denominator definition, cluster attribution or outcome ascertainment;
  • belonging to clusters that are not classifiable, mappable or randomizable.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Control

Standard communication: standard e-mail informing that the vaccination campaing is ongoing and inviting healthcare workers to participate.

Dear Colleague,

The seasonal flu vaccination campaign is underway.

If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided.

Thank you for your attention and for contributing to this prevention effort.

Experimental: Gain Framing

Gain framing: e-mail emphasising the benefits of vaccination for the worker, patients, colleagues and the organisation.

Dear Colleague,

The seasonal flu vaccination campaign is underway.

Flu is not always a mild illness. Globally, it is estimated to cause 3-5 million cases of severe illness and 290,000-650,000 deaths associated with respiratory disease each year. In Italy, more than 21,000 hospital admissions each year are attributable to flu or related respiratory and cardiovascular complications.

Getting vaccinated against flu protects both individual and community health:

  • It reduces the spread of the flu virus, benefiting care recipients, patients, colleagues, and family members.
  • It reduces the risk of complications in people with chronic conditions.
  • It reduces the risk of a heart attack in the seven days following a confirmed flu infection.

If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided.

Thank you for your attention and for contributing to this prevention effort.

Experimental: Loss framing

Loss framing: e-mail emphasising the risks and potential negative consequences of non-vaccination for the worker, patients, colleagues and the organisation.

Dear Colleague,

The seasonal flu vaccination campaign is underway.

Flu is not always a mild illness. Globally, it is estimated to cause 3-5 million cases of severe illness and 290,000-650,000 deaths associated with respiratory disease each year. In Italy, more than 21,000 hospital admissions each year are attributable to flu or related respiratory and cardiovascular complications.

Not getting vaccinated against flu increases both individual and community risks:

  • It increases the spread of the flu virus, affecting care recipients, patients, colleagues, and family members.
  • It increases the risk of complications in people with chronic conditions.
  • It increases the risk of a heart attack in the seven days following a confirmed flu infection.

If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided.

Thank you for your attention and for contributing to this prevention effort.

Experimental: Social norms

Social norms: weekly e-mails providing updates on campaign progress and comparison between the vaccination uptake rate of the recipient's cluster and that of other clusters assigned to the same experimental arm.

Dear Colleague,

The seasonal flu vaccination campaign is underway.

To encourage staff vaccination, the Agency will send a brief weekly update on the campaign's progress from now through December. These updates will compare vaccination rates across selected organizational units within the Agency. The units were selected at random and were formed by grouping organizational structures with similar areas of activity.

If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided.

Thank you for your attention and for contributing to this prevention effort.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Influenza vaccination uptake at the end of 2026-2027 campaign.
Periodo de tiempo: Up to 6 months

Proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination by the end of the observation period of the campaign.

Up to 6 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Influenza vaccination uptake at mid 2026-2027 campaign.
Periodo de tiempo: Up to 3 months

Proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination at mid of the campaign.

Up to 3 months
Change in influenza vaccination uptake between seasons.
Periodo de tiempo: Baseline and 6 months

Absolute percentage-point change in influenza vaccination uptake between the 2026-2027 campaign and the 2025-2026 campaign.

Baseline and 6 months
Time to vaccination.
Periodo de tiempo: Up to 6 months

The number of days between the delivery of the communication assigned to the cluster and the documented date of influenza vaccination.

Up to 6 months
Sickness absence.
Periodo de tiempo: Up to 6 months

Number of sickness absence days and/or sickness absence rates standardised by eligible population or person-time.

Up to 6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

21 de octubre de 2026

Finalización primaria (Estimado)

31 de marzo de 2027

Finalización del estudio (Estimado)

31 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

30 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

No IPD data will be collected as part of the study.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir